Pregnancy Outcomes in Men and Women Treated With Teriflunomide. A Population-Based Nationwide Danish Register Study

Background: The majority of persons diagnosed with multiple sclerosis (MS) experience their first MS symptoms in the reproductive age. Teriflunomide (TFL, Aubagio), was first released in Denmark for relapsing-remitting MS in December 2013. TFL treatment is contraindicated in women of childbearing po...

Descripción completa

Detalles Bibliográficos
Autores principales: Andersen, Johanna Balslev, Moberg, Julie Yoon, Spelman, Tim, Magyari, Melinda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6266987/
https://www.ncbi.nlm.nih.gov/pubmed/30532753
http://dx.doi.org/10.3389/fimmu.2018.02706

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6266987/
https://www.ncbi.nlm.nih.gov/pubmed/30532753
http://dx.doi.org/10.3389/fimmu.2018.02706

Ejemplares similares